NL-OMON23516尚未招募不适用
BioMonitor III: Validation of the Atrial fibrillation Detecting algorithm in patients undergoing pulmonary vein isolation
Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- •1.Diagnosis of paroxysmal or persistent AF
- •2.Subject scheduled to undergo PVI within 6 months
- •3.Subject willing and able to comply with the follow-up requirements of the study
- •4.Written informed consent obtained from subject aged 18 years or older
排除标准
- •A potential subject who meets any of the following criteria will be excluded from participation in this study:
- •1.Diagnosis of long-standing persistent AF
- •2.Subjects implanted with a previous ICM, pacemaker, implantable cardioverter defibrillator or cardiac resynchronization therapy device
- •3.Subjects with an active infection
- •4.Subjects enrolled in another clinical study which may confound the results of this study
- •5.Subjects with a life expectancy of <1 year due to any condition
研究者
相似试验
已完成
不适用
BioMonitor III: Validation of the Atrial fibrillation Detecting algorithm in patients undergoing pulmonary vein isolatioirregular heart rhythm10007521Atrial fibrillationNL-OMON48234Erasmus MC, Universitair Medisch Centrum Rotterdam30
进行中（未招募）
不适用
Study to investigate the ability of a blood-derived score to select patients with relapsing multiple sclerosis who benefit from treatment with human immune globulirelapsing multiple sclerosisMedDRA version: 17.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2012-005086-12-HUOctapharma AG216
进行中（未招募）
不适用
Study to investigate the ability of a blood-derived score to select patients with relapsing multiple sclerosis who benefit from treatment with human immune globuliEUCTR2012-005086-12-ATOctapharma AG216
进行中（未招募）
不适用
Study to investigate the ability of a blood-derived score to select patients with relapsing multiple sclerosis who benefit from treatment with human immune globulirelapsing multiple sclerosisMedDRA version: 18.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2012-005086-12-BGOctapharma AG234
进行中（未招募）
不适用
Study to investigate the ability of a blood-derived score to select patients with relapsing multiple sclerosis who benefit from treatment with human immune globulirelapsing multiple sclerosisMedDRA version: 17.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2012-005086-12-DEOctapharma AG216